Cargando…

Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice

BACKGROUND: The value of normal C-reactive protein (CRP) in psoriatic arthritis (PsA) is debatable. OBJECTIVES: To test the hypothesis that CRP is frequently normal in contemporary real-world PsA patients, despite active disease. DESIGN: In this cross-sectional study, patients were divided into two...

Descripción completa

Detalles Bibliográficos
Autores principales: Gialouri, Chrysoula G., Evangelatos, Gerasimos, Pappa, Maria, Karamanakos, Anastasios, Iliopoulos, Alexios, Tektonidou, Maria G., Sfikakis, Petros P., Fragoulis, George E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445451/
https://www.ncbi.nlm.nih.gov/pubmed/36081746
http://dx.doi.org/10.1177/1759720X221122417
_version_ 1784783425631158272
author Gialouri, Chrysoula G.
Evangelatos, Gerasimos
Pappa, Maria
Karamanakos, Anastasios
Iliopoulos, Alexios
Tektonidou, Maria G.
Sfikakis, Petros P.
Fragoulis, George E.
author_facet Gialouri, Chrysoula G.
Evangelatos, Gerasimos
Pappa, Maria
Karamanakos, Anastasios
Iliopoulos, Alexios
Tektonidou, Maria G.
Sfikakis, Petros P.
Fragoulis, George E.
author_sort Gialouri, Chrysoula G.
collection PubMed
description BACKGROUND: The value of normal C-reactive protein (CRP) in psoriatic arthritis (PsA) is debatable. OBJECTIVES: To test the hypothesis that CRP is frequently normal in contemporary real-world PsA patients, despite active disease. DESIGN: In this cross-sectional study, patients were divided into two groups: CRP ⩽ 0.5 mg/dl (normal) and CRP > 0.5 mg/dl (increased). Having as dependent variable the CRP status, these groups were compared for disease-related features, including composite disease activity indices [clinical Disease Activity in PSoriatic Arthritis (cDAPSA) and minimal disease activity (MDA)] and patient-reported outcomes (PROs). Agreement between CRP status and cDAPSA/MDA scores was calculated (Cohen’s kappa). METHODS: Data from consecutive PsA patients attending two outpatient rheumatology clinics (January 2019–June 2021) were analysed. RESULTS: From 128 patients enrolled (51.6% females; mean ± standard deviation age: 53.4 ± 11.7 years; 23.4%, 48.4% and 64.1% treated with glucocorticoids, conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and biologic DMARDs, respectively), two-thirds (66.4%, n = 85) had normal CRP values. CRP status was not associated with any of the disease-related parameters and PROs, but only with ESR [odds ratio: 1.04 (95% confidence interval: 1.01–1.06), p = 0.005]. Among patients with normal CRP, 45.9% (39/85) were on non-MDA state, while 21.2% (18/85) had cDAPSA-moderate and 5.9% (5/85) had cDAPSA-high disease activities. Conversely, 54.2% (39/72) of patients on non-MDA state and 52.3% (23/44) of those with cDAPSA-moderate or cDAPSA-high disease activity had normal CRP values. Cohen’s kappa between normal CRP and MDA, cDAPSA-remission, and cDAPSA-remission/low disease activity was –0.26, –0.21 and –0.22, respectively, displaying total disagreement. CONCLUSION: Normal CRP in PsA should not be used as surrogate marker of remission or low/MDA, therefore needs to be interpreted with caution in clinical decision-making.
format Online
Article
Text
id pubmed-9445451
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-94454512022-09-07 Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice Gialouri, Chrysoula G. Evangelatos, Gerasimos Pappa, Maria Karamanakos, Anastasios Iliopoulos, Alexios Tektonidou, Maria G. Sfikakis, Petros P. Fragoulis, George E. Ther Adv Musculoskelet Dis Original Research BACKGROUND: The value of normal C-reactive protein (CRP) in psoriatic arthritis (PsA) is debatable. OBJECTIVES: To test the hypothesis that CRP is frequently normal in contemporary real-world PsA patients, despite active disease. DESIGN: In this cross-sectional study, patients were divided into two groups: CRP ⩽ 0.5 mg/dl (normal) and CRP > 0.5 mg/dl (increased). Having as dependent variable the CRP status, these groups were compared for disease-related features, including composite disease activity indices [clinical Disease Activity in PSoriatic Arthritis (cDAPSA) and minimal disease activity (MDA)] and patient-reported outcomes (PROs). Agreement between CRP status and cDAPSA/MDA scores was calculated (Cohen’s kappa). METHODS: Data from consecutive PsA patients attending two outpatient rheumatology clinics (January 2019–June 2021) were analysed. RESULTS: From 128 patients enrolled (51.6% females; mean ± standard deviation age: 53.4 ± 11.7 years; 23.4%, 48.4% and 64.1% treated with glucocorticoids, conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and biologic DMARDs, respectively), two-thirds (66.4%, n = 85) had normal CRP values. CRP status was not associated with any of the disease-related parameters and PROs, but only with ESR [odds ratio: 1.04 (95% confidence interval: 1.01–1.06), p = 0.005]. Among patients with normal CRP, 45.9% (39/85) were on non-MDA state, while 21.2% (18/85) had cDAPSA-moderate and 5.9% (5/85) had cDAPSA-high disease activities. Conversely, 54.2% (39/72) of patients on non-MDA state and 52.3% (23/44) of those with cDAPSA-moderate or cDAPSA-high disease activity had normal CRP values. Cohen’s kappa between normal CRP and MDA, cDAPSA-remission, and cDAPSA-remission/low disease activity was –0.26, –0.21 and –0.22, respectively, displaying total disagreement. CONCLUSION: Normal CRP in PsA should not be used as surrogate marker of remission or low/MDA, therefore needs to be interpreted with caution in clinical decision-making. SAGE Publications 2022-09-05 /pmc/articles/PMC9445451/ /pubmed/36081746 http://dx.doi.org/10.1177/1759720X221122417 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Gialouri, Chrysoula G.
Evangelatos, Gerasimos
Pappa, Maria
Karamanakos, Anastasios
Iliopoulos, Alexios
Tektonidou, Maria G.
Sfikakis, Petros P.
Fragoulis, George E.
Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice
title Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice
title_full Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice
title_fullStr Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice
title_full_unstemmed Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice
title_short Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice
title_sort normal c-reactive protein in active psoriatic arthritis: results from real-world clinical practice
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445451/
https://www.ncbi.nlm.nih.gov/pubmed/36081746
http://dx.doi.org/10.1177/1759720X221122417
work_keys_str_mv AT gialourichrysoulag normalcreactiveproteininactivepsoriaticarthritisresultsfromrealworldclinicalpractice
AT evangelatosgerasimos normalcreactiveproteininactivepsoriaticarthritisresultsfromrealworldclinicalpractice
AT pappamaria normalcreactiveproteininactivepsoriaticarthritisresultsfromrealworldclinicalpractice
AT karamanakosanastasios normalcreactiveproteininactivepsoriaticarthritisresultsfromrealworldclinicalpractice
AT iliopoulosalexios normalcreactiveproteininactivepsoriaticarthritisresultsfromrealworldclinicalpractice
AT tektonidoumariag normalcreactiveproteininactivepsoriaticarthritisresultsfromrealworldclinicalpractice
AT sfikakispetrosp normalcreactiveproteininactivepsoriaticarthritisresultsfromrealworldclinicalpractice
AT fragoulisgeorgee normalcreactiveproteininactivepsoriaticarthritisresultsfromrealworldclinicalpractice